Rodney Coe, MD
Retina Specialist · Bayside, NYNPI 1003972548
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $9,701 of the $15,605 with a category attached, or 62.2%. 20 manufacturers reported payments, led by Regeneron at 33.3% of the total.
Across 100 payments — averaging $156.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$5K
- AbbVie$5K
- Regeneron Healthcare Solutions, Inc.$2K
- Genentech USA, Inc.$548
- Apellis Pharmaceuticals, Inc.$490
- Eyevance Pharmaceuticals LLC$310
- plus $2K from 14 others
What the payments were for
- Consulting fees$9,70162%
- Travel & lodging$640%
- Food & beverage$5,84037%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 7 | $5,197 |
| AbbVie(2 entities) | 11 | $5,007 |
| Regeneron Healthcare Solutions, Inc. | 23 | $1,843 |
| Genentech USA, Inc. | 13 | $548 |
| Apellis Pharmaceuticals, Inc. | 8 | $490 |
| Eyevance Pharmaceuticals LLC | 2 | $310 |
| Bausch & Lomb Americas Inc. | 2 | $275 |
| Sun Pharmaceutical Industries Inc. | 4 | $256 |
| Astellas Pharma US Inc | 11 | $250 |
| Alcon | 2 | $228 |
| Topcon Healthcare, Inc. | 1 | $220 |
| Eyepoint US, Inc. | 2 | $199 |
| Harrow Eye, LLC | 3 | $187 |
| Astellas Pharma Global Development | 4 | $127 |
| Tarsus Pharmaceuticals, Inc. | 1 | $124 |
| Recordati_rare_diseases_inc. | 1 | $122 |
| NEW World Medical,inc. | 1 | $98 |
| Carl Zeiss Meditec, Inc. | 1 | $70 |
| Novartis | 2 | $39 |
| Oyster Point Pharma, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA HD$5,935
- OZURDEX$4,633
- EYLEA$747
- VABYSMO$358
- Syfovre$347
- Tobradex ST$310
- enVista MX60 IOL$150
- MIEBO$125
- XIIDRA$125
- XDEMVY$124
- CYSTADROPS$122
- Clareon$121
- YUTIQ$117
- CEQUA$116
- AcrySof IQ PanOptix UV IOL$106
- AcrySof IQ VIVITY$106
How this compares
$15,605 in reported general payments places this provider in the 85th percentile of 99 retina specialist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EyleaAflibercept | 15 | $32,553 |
| XiidraLifitegrast | 11 | $9,047 |
| Loteprednol Etabonate | 12 | $2,544 |
| Difluprednate | 19 | $2,180 |
| CombiganBrimonidine Tartrate/Timolol | 11 | $2,100 |
| Bromfenac Sodium | 16 | $2,001 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 15 | $417 |
| Latanoprost | 28 | $181 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Regeneron Healthcare Solutions, Inc.Eylea | $1,843 | $32,55315 claims |
| Bausch & Lomb Americas Inc.Xiidra | $275 | $9,04711 claims |
| AbbVieCombigan | $5,007 | $2,10011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 99 retina specialist providers in New York.
Other retina specialist in Bayside
- Paul HahnNanuet$238K
- Deepika MalikWoodbury$221K
- Szilard KissNew York$195K
- Ferhina AliValhalla$176K
- Donald D'amicoNew York$109K
- Matthew WitmerRochester$62K
- Avnish DeobhaktaBrooklyn$46K
- Edward HallRochester$38K
- Philip NilesWilliamsville$30K
- Mark BreazzanoLiverpool$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.